Abstract 731: Integrating ctDNA and FDG-PET dynamics to predict pathological response following neoadjuvant systemic therapy in stage III melanoma
Wei Yen Chan(Melanoma Institute Australia), Helen Rizos(Macquarie University), George Au‐Yeung(The University of Melbourne), Russell J. Diefenbach(The University of Sydney), Georgina V. Long(The University of Sydney), Robyn P.M. Saw(Melanoma Institute Australia), Matteo S. Carlino(The University of Sydney), Ashleigh Stewart(The University of Sydney), Richard A. Scolyer(The University of Sydney), Edward C. Hsiao(University of California, San Francisco), Andrew J. Spillane(Melanoma Institute Australia), Jenny Lee(Blacktown & Mount Druitt Hospital), Maria Gonzalez(The University of Sydney), Li Zhou(North Sichuan Medical University), Sydney Ch'ng(Melanoma Institute Australia), Alexander M. Menzies(The University of Sydney)
Cited by 0
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
|The Lancet Oncology|2012|906